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A B S T R A C T
Objectives: Human T-cell lymphotropic virus type 1 (HTLV-1) infection leads to the risk of developing
HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in less than 5% of cases. The
mechanism of disease progression in HAM/TSP remains unknown. A signiﬁcant role of certain human
leukocyte antigen (HLA) genotypes in determining the risk of HAM/TSP has been reported in Japan, where
the HLA-A*02 gene has been found to be associated with a lower HTLV-1 provirus load and with
protection from HAM/TSP, whereas HLA-DRB1*0101 has been found to be associated with an increased
susceptibility to HAM/TSP. The aim of the present case–control study was to investigate the HLA class I
and class II allele distribution in HTLV-seropositive French Afro-Caribbean individuals, originating from
the French West Indies.
Methods: Associations with HLA class I (A and B) and class II (DRB1 and DQB1) alleles were tested in 123
HAM/TSP patients and 85 asymptomatic HTLV-1 carriers. HLA typing was undertaken on genomic DNA
extracted from peripheral blood leukocytes.
Results: In our cohort, no signiﬁcant effect on either the risk of developing HAM/TSP or HTLV-1 provirus
load was found for HLA class I or class II, including HLA-A*02 (p = 0.43).
Conclusions: Our ﬁndings are in contrast to those in the Japanese population, however the literature on
HLA associations in HTLV-1 infections across different populations over the past decade have reported
conﬂicting results and this suggests strong ethnic disparities.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Tropical spastic paraparesis (TSP)was ﬁrst reported by Strachan
in the late 19th century1 and was described clinically in a large
series of patients from the West Indies by Cruickshank in 1956.2
Discovered in 1980, human T-cell lymphotropic virus type 1
(HTLV-1) was identiﬁed as the etiological agent of adult T-cell
leukemia (ATL).3 HTLV-1-associated myelopathy (HAM) was
described by Gessain et al. in 1985,4 followed by Osame et al.5
in Japan in 1986. In 1988, the World Health Organization (WHO)
recommended ‘‘that the disease be known by the acronym HAM/
TSP for the time being’’.6
The infection is estimated to affect 10 to 20 million people and
HTLV-1 is widespread in the tropics and subtropics.6–8 There are* Corresponding author.
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doi:10.1016/j.ijid.2010.05.020large endemic foci in the Caribbean, southern Japan, Central and
South Africa, and South America, particularly Brazil. HTLV-1 is also
present in southern Africa, southern India, northern Iran, the
aboriginal populations of northern Australia, and many islands in
the tropics. InEuropeandNorthAmerica, the virus is foundchieﬂy in
certain immigrant groups and in intravenous drug users. The
infection is mainly blood borne. The dominant modes of transmis-
sion of HTLV-1 in endemic areas are from mother to child in breast
milk and by sexual transmission in adults. Male to female sexual
transmission is about four times as frequent as female to male
transmission.9,10 In1999, the seroprevalence inMartinique, a French
island in the Caribbean basin, was estimated to be 2.2%.11
HTLV-1 has a preferential tropism for CD4+ T cells and to a
lesser extent for CD8+ T cells. After its entry into the cell, the virus
is present as a provirus incorporated into the DNA of lympho-
cytes.12 Viral replication of HTLV-1 in carriers is very low or even
absent and therefore these infected silent cells are undetectable by
the immune system for a long period of time. In spite of theses. Published by Elsevier Ltd. All rights reserved.
Table 1
Characteristics of patients with HAM/TSP and of healthy HTLV-1 carriers
HAM/TSP Asymptomatic p-Value
n 123 85
Age, mean SD, years 62.27 (1.33) 56.73 (1.75) 0.01
Sex, n
Female 103 59 0.014
Male 20 26
Gender ratio (M/F) 0.19 0.44
Follow-up duration, years
Mean SD 13.34.38 13.74.7 0.517
Median 14 14
Range 7–26 5–21
HTLV-1 proviral load, copies/106 PBMCs
n 113 67
Mean SD 83 180.9 (75 658) 23 335.2 (30 902) <0.0001
Median 67 740 9780 <0.0001
HAM/TSP, HTLV-1-associated myelopathy/tropical spastic paraparesis; HTLV-1, human T-lymphotropic virus type 1; SD, standard deviation; PBMCs, peripheral blood
mononuclear cells.
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be caused by retroviruses, less than 10% of infected individuals
develop HTLV-1-associated diseases in general, including ATL and
HAM/TSP, by mechanisms that are incompletely under-
stood.3,5,13,14
HAM/TSP is a slowly progressive disabling disorder character-
ized by spastic paraparesis with bladder and bowel dysfunction
and lower back pain.15,16 The disease course of HAM/TSP appears
to be non-homogeneous and a subgroup of patients experiences
rapid disease progression, particularly in post-transfusional and
post-transplantation cases. In Martinique (FrenchWest Indies) the
prospective observation of a cohort of 132 HAM/TSP patients over
14 years showed that the median time from disease onset to the
assignment of a disability status score (DSS)17 of 6 (ability to walk
with unilateral support 100 m without rest) was 6 years, to a
score of 6.5 (need of bilateral aid towalk 20 m)was 13 years, and to
a score of 8 (essential restriction to awheelchair) was 21 years. The
median time from DSS 6 to 8 was 8 years. DSS 10 (death related to
the disease) was reached by a quarter of the patients within 20
years.18
It is estimated that among HTLV-1 carriers, the lifetime
cumulative risk of developing HAM/TSP ranges from 0.3% to 4%.14
Several parameters may inﬂuence this conversion, including age,
route of infection, high provirus load, and host immunological and
genetic factors. Twenty years ago, Usuku et al. ﬁrst suggested that
the magnitude of the immune response in HAM/TSP was in part
regulated by the immune response genes associatedwith the host’s
major histocompatibility complex.19 The most convincing studies
were performed on the Kagoshima population in Japan. The authors
demonstrated a clear protective effect of the human leukocyte
antigenHLA-A*02andHLA-Cw*08alleles againstHAM/TSP inHTLV-
1-infected individuals, whereas HLA-DRB1*0101 and HLA-B*5401
were found to be associated with an increased susceptibility to
HAM/TSP.20,21 The association of HLA-DRB1*0101 with disease
susceptibilitywasonlyevident in theabsenceof theprotectiveeffect
of HLA-A*02. Moreover, these data were enhanced by the
independent associations found between HLA-A*02 genes and a
lower HTLV-1 provirus load. Since HTLV-1 contains a dominant A2-
restricted epitope, individuals with the HLA-A*02 allele would
develop a stronger cytotoxic T-lymphocyte response against HTLV-
1, leading to a provirus load decrease. The high prevalence in the
humanpopulation and the associationwith proviral load has shown
HLA-A*02 to be one of the best candidate genes associated with
HAM/TSP conversion among HTLV-1 carriers .
The same authors reported the data from a small sample of 29
HTLV-1 carriers from London, of which 27 were of Caribbean
origin, with the same results of a protective effect for A*02 in HAM/TSP: 10 of 14 asymptomatic HTLV-1 carriers were HLA-A*02-
positive, compared with four of 15 HAM/TSP patients (p = 0.02,
Fisher’s exact test).20
We performed a case–control study to investigate the possible
associations of HLA class I (A and B) and class II (DRB1 and DQB1)
alleles with HAM/TSP and/or with HTLV-1 provirus load in a large
cohort of Afro-Caribbean HTLV-1 carriers followed up in our
neurology department.
2. Materials and methods
2.1. Study subjects
The studywas carried out inMartinique, an island of the French
West Indies situated in the Caribbean Lesser Antilles (148300N–
618W). One hundred twenty-three consecutive patients who
fulﬁlled the WHO diagnostic criteria of HAM/TSP22 and 85
consecutive blood asymptomatic HTLV-1 healthy carriers (HCs)
followed up in the Department of Neurology, University Hospital of
Fort-de-France were recruited. Characteristics of the subjects with
HAM/TSP and the HCs are shown in Table 1. As expected, the
gender difference between the two groups of HTLV-1 carriers
showed a female predominance, mainly in HAM/TSP patients,
similar to the results of epidemiological studies.
2.2. HLA typing
Genomic DNA was extracted from peripheral blood leukocytes
using the salting out method.23 HLA class I (A and B) and class II
(DRB1 and DQB1) typing was determined by polymerase chain
reaction with sequence-speciﬁc oligonucleotides (PCR-SSO), using
a reverse dot-blot hybridization method (RDB) as previously
reported,24 and according to themanufacturer’s recommendations
(INNO-LiPA tests from Innogenetics). Brieﬂy, after speciﬁc
ampliﬁcation of each locus, the PCR biotinylated product is
hybridized with speciﬁc oligonucleotide probes immobilized as
parallel lines on membrane-based strips. After hybridization,
streptavidin labeled with alkaline phosphatase binds to any
biotinylated hybrid, and incubation with the chromogene results
in a colored precipitate. The hybridization and coloration steps
were performed in an Auto-LiPA apparatus (Innogenetics, Bel-
gium). Positive band patterns were automatically scanned (LiPA
Scan) and HLA typing was interpreted using Inno-LiPA interpreta-
tion software. For the analysis of HLA class II, 62 probes were used
for DRB1 typing, 21 for DQB1 typing, and 21 for DPB1 typing. The
same conditions of hybridization and washing temperatures were
used whatever the locus considered, allowing the simultaneous
Table 2
Phenotype frequency of HLA class I and class II alleles in HAM/TSP patients and healthy HTLV-1 carriers
HAM/TSP Asymptomatic Chi-square OR 95% CI p-Valuea Corrected p-value
HLA-A n=117 (%)b n=83 (%)c
A01 12 (10.3) 10 (12.0) 0.16 0.83 0.34–2.02 0.690 NS
A02 40 (34.2) 24 (28.9) 0.62 1.28 0.7–2.35 0.431 NS
A03 23 (19.7) 16 (19.3) 0 1.02 0.5–2.08 0.947 NS
A23 20 (17.1) 10 (12.0) 0.97 1.51 0.67–3.42 0.325 NS
A24 13 (11.1) 5 (6.0) 1.53 1.95 0.67–5.62 0.215 NS
A28 23 (19.7) 7 (8.4) 4.8 2.66 1.08–6.53 0.028 NS
A29 6 (5.1) 5 (6.0) 0.07 0.84 0.25–2.85 0.784 NS
A30 17 (14.5) 22 (26.5) 4.44 0.47 0.23–0.95 0.035 NS
A33 20 (17.1) 13 (15.7) 0.07 1.11 0.52–2.38 0.788 NS
A36 8 (6.8) 8 (9.6) 0.52 0.69 0.25–1.92 0.472 NS
A74 12 (10.3) 14 (16.9) 1.88 0.56 0.24–1.28 0.171 NS
HLA-B n=117 (%)b n=83 (%)c
B07 21 (17.9) 16 (19.3) 0.06 0.92 0.45–1.89 0.812 NS
B15 10 (8.5) 13 (15.7) 2.42 0.5 0.21–1.2 0.12 NS
B35 32 (27.4) 20 (24.1) 0.27 1.19 0.62–2.29 0.605 NS
B42 12 (10.3) 7 (8.4) 0.19 1.24 0.47–3.3 0.665 NS
B44 17 (14.5) 15 (18.1) 0.45 0.77 0.36–1.65 0.501 NS
B45 17 (14.5) 7 (8.4) 1.71 1.85 0.73–4.69 0.191 NS
B53 30 (25.6) 17 (20.5) 0.72 1.34 0.68–2.63 0.397 NS
B57 9 (7.7) 10 (12.0) 1.07 0.61 0.24–1.57 0.301 NS
B58 6 (5.1) 7 (8.4) 0.87 0.59 0.19–1.82 0.35 NS
HLA-DR n=123 (%) n=85 (%)
DR01 20 (14.0) 14 (16.5) 0 0.98 0.46–2.07 0.968 NS
DR03 27 (21.9) 20 (23.5) 0.07 0.91 0.47–1.76 0.789 NS
DR04 7 (5.7) 7 (8.2) 0.52 0.67 0.23–1.99 0.472 NS
DR07 19 (15.4) 20 (23.5) 2.16 0.59 0.29–1.19 0.142 NS
DR08 12 (9.8) 11 (12.9) 0.52 0.73 0.31–1.74 0.471 NS
DR09 8 (6.5) 7 (8.2) 0.23 0.78 0.27–2.24 0.635 NS
DR11 37 (30.1) 12 (14.1) 7.11 2.62 1.27–5.39 0.008 NS
DR12 9 (7.3) 5 (5.9) 0.16 1.26 0.41–3.9 0.685 NS
DR13 40 (32.5) 33 (38.8) 0.88 0.76 0.43–1.35 0.349 NS
DR15 47 (38.2) 21 (24.7) 4.17 1.88 1.02–3.47 0.041 NS
HLA-DQ n=123 (%) n=85 (%)
DQ02 39 (31.7) 36 (42.4) 2.47 0.63 0.35–1.12 0.116 NS
DQ03 45 (36.6) 30 (35.3) 0.04 1.06 0.6–1.89 0.849 NS
DQ04 19 (15.4) 8 (9.4) 1.62 1.76 0.73–4.23 0.203 NS
DQ05 42 (34.1) 35 (41.2) 1.07 0.74 0.42–1.31 0.302 NS
DQ06 69 (56.1) 36 (42.4) 3.8 1.74 1.0–3.04 0.051 NS
HAM/TSP, HTLV-1-associated myelopathy/tropical spastic paraparesis; HTLV-1, human T-lymphotropic virus type 1; OR, odds ratio (obtained by Woolf’s method); CI,
conﬁdence interval; NS, not signiﬁcant.
Alleles with a frequency of <5% are not reported.
a p-Values obtained by Chi-square test; signiﬁcant p-values before Bonferroni’s correction are shown in bold.
b Unable to type DNA in six samples
c Unable to type DNA in two samples.
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ture of the HLA alleles was as per the WHO Nomenclature
Committee.
2.3. HTLV-1 proviral load in peripheral blood mononuclear cells
(PBMCs)
HTLV-1 proviral load in peripheral blood mononuclear cells
(PBMCs) was quantiﬁed in the HAM/TSP patients and asymptom-
atic carriers. PBMCs were isolated from ethylenediaminetetraa-
cetic acid (EDTA) blood by density gradient centrifugation and
cryopreserved until use. DNA was extracted using a spin column
DNA extraction system (GFXtm PCR DNA, Amersham Pharmacia
Biotech, USA). HTLV-1 proviral load was quantiﬁed using a real-
time Taq-Man PCR method, as described previously.25,26 The value
for the HTLV-1 proviral load was reported as the [(HTLV-1 average
copy number)/(albumin average copy number)]  2  106 PBMCs
and expressed as the number of HTLV-1 copies per 106 PBMCs.
HTLV-1 proviral load was measured in 113 (91.9%) HAM/TSP
patients and in 67 (78.8%) HCs. As expected, HAM/TSP patients had
a signiﬁcantly higher median proviral load than HCs (67 740/106
PBMCs, range 1456–391 990 vs. 9780/106 PBMCs, range 29–119
638; p < 0.0001, Mann–Whitney test) (Table 1).2.4. Statistical analysis
The frequencies of individuals carrying HLA class I (A and B) and
class II (DRB1 and DQB1) alleles (phenotype frequencies) were
calculated and compared between HAM/TSP patients and HCs
using the Chi-square test. Odds ratios (OR) were obtained by
Woolf’s method. Only allele groups with frequencies >5% were
considered in the analysis. The level of signiﬁcance was taken as
p < 0.05. For allelic comparisons, Bonferroni’smethodwas used for
the correction of multiple comparisons, multiplying the p-value
obtained in the statistical test by the total number of alleles tested.
3. Results
HLA class I (A and B) and class II (DRB1 and DQB1) allelic
frequencies in HAM/TSP patients and asymptomatic HTLV-1
carriers are displayed in Table 2.
3.1. HLA class I (A and B) and class II (DRB1 and DQB1) and risk of
HAM/TSP
The distributions of HLA class I (A and B) and class II (DRB1 and
DQB1) alleles were quite similar between HAM/TSP patients and
Table 3
HLA allele inﬂuence on HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) disease in previous studies
Country and year HAM-TSP/HCs HLA tested Effect Reference
Jamaica, 1998 54/45 HLA class II (DRB1, DQB1) No effect 28









Brazil, 2003 NA HLA class I (A, B)
and class II (DRB1)
HLA-A*02: tendency to protective effect only in ‘white’ patients (NS)
HLA-DRB1*11: tendency to susceptible in ‘mestizo’ patients (NS)
30




HLA-A*02 and HLA-Cw*08: no effect
HLA-DRB1*0101: susceptible only in HLA-A*02-negative patients
HLA-B*5401: not found in the subjects analyzed
27
Jamaica, 2007a 59/190 HLA class I (A, B)
and class II (DRB1, DQB1)
No effect 29
Brazil, 2009 9/84 HLA class I (A,
B, and Cw)
HLA-A*02: tendency to protective effect (NS)
HLA-Cw*08: no effect
HLA-Cw*07: susceptible only in
HLA-A*02-negative patients
31
Martinique, 2010a 123/85 HLA class I (A, B),
and class II (DRB1, DQB1)
No effect Present study
HLA, human leukocyte antigen; HTLV-1, human T-lymphotropic virus type 1; HCs, healthy controls; NS, not signiﬁcant; NA, not available.
a Studies with HTLV-1 provirus load measurements.
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atic and asymptomatic HTLV-1 individuals (p = 0.431), and a lower
frequency of HLA-A*02 was even observed in the HCs compared
with HAM/TSP patients (28.9% vs. 34.2%). Moreover, we found no
consistent correlation between HLA-DRB1*01 with disease sus-
ceptibility (p = 0.978). Furthermore, in HLA-A*02-negative sub-
jects, HLA-DRB1*01 was not correlated with HAM/TSP (p = 0.838)
(Table 3).
Compared with the asymptomatic group, the HAM/TSP group
presented only a tendency to a higher frequency of the HLA-DR*11
alleles (OR 2.62, p = 0.008, corrected p not signiﬁcant) and HLA-
DR*15 alleles (OR 1.88, p = 0.041, corrected p not signiﬁcant).
3.2. HLA class I (A and B) and class II (DRB1 and DQB1) and
proviral load
No HLA class I or II allele was associated with provirus load in
HTLV-1-infected individuals, HAM/TSP patients or HCs. We
particularly focused on HLA-A*02 and HLA-DRB1*01, and we
failed to show any correlation between these alleles and the level
of proviral loads in HTLV-1-infected individuals (p = 0.49 and
p = 0.85, respectively) or HCs (p = 0.73 and p = 0.35, respectively).
Neither the HLA-DRB1*11 or HLA-DRB1*15 alleles were signiﬁ-
cantly associated with provirus load (p = 0.65 and p = 0.12,
respectively).
4. Discussion
In our population, HLA class I (A and B) and class II (DRB1 and
DQB1) had no signiﬁcant effect on either the risk of developing
HAM/TSP or HTLV-1 provirus load. We only found a tendency to a
higher frequency of HLA-DRB1*11 and HLA-DRB1*15 alleles in
HAM/TSP patients than in HCs. HLA-A*02 had no signiﬁcant effect
on the risk of HAM/TSP. This result is in contrast with reports on
Japanese patients,20,21 but in accordance with some previous
studies in Iranian27 and Jamaican populations28,29 (Table 3 shows
the HLA alleles investigated in case–control studies of HAM/TSP in
various populations, according to data gathered from the available
literature). Borducchi et al. found only a tendency to a lower HLA-
A*02 frequency in the subgroup of ‘white’ HAM/TSP patients in a
Brazilian population (31.2% vs. 47.0%; p < 0.09).30 In a quite similar
Brazilian cohort, a low frequency of HLA-A*02 was observed inHAM/TSP patients when compared to HCs (33% vs. 47%), but
statistical analysis was not possible because of the small sample
size in the HAM/TSP group (only nine patients vs. 84 asymptom-
atic).31 The HLA-B*54 allele, which is an important risk factor for
disease conversion in Japanese individuals,21 was not relevant in
our Afro-Caribbean population, or in Iranians or Brazilians.
In Japanese patients, in contrast to HLA-A*02, HLA-DRB1*0101
was associated with susceptibility to HAM/TSP (p = 0.049). This
predisposition was only signiﬁcant in HLA-A*02-negative patients
and disappeared in HLA-A*02-positive patients .20 Similar results
were found in HTLV-1 Iranian individuals. HLA-DRB1*0101 was
associated with a signiﬁcantly lower provirus load in Japanese
symptomatic patients (p = 0.024), but this effect was not observed
in Japanese asymptomatic carriers, nor in the HAM/TSP or
asymptomatic Iranian subjects.27 In our study, we failed to show
any correlation between HLA-DRB1*01 and the risk of HAM/TSP
(even in non-HLA-A*02 subjects) or with proviral load. In
Jamaican28,29 and Brazilian populations,30 no relationship was
found between HLA-DRB1*0101 and HAM/TSP risk. It should be
noted that analysis of molecular subtyping was not done in our
study for economic reasons, and we could not exclude a potential
susceptibility effect of HLA-DRB1*0101.
We showed that HLA-DR11 tended toward a higher frequency
in HAM/TSP patients and this association has previously been
described in Japanese19 and Brazilian mestizo patients.30 As is
often the case, the opposite ﬁnding was reported in a Jamaican
population of HTLV-1-infected subjects.28
These conﬂicting and sometimes opposing results of associa-
tion between HAM/TSP and HLA alleles in different ethnic groups
may reﬂect different pathogenic mechanisms occurring in each
population. Indeed, although HTLV-1 has a very stable genome,
molecular epidemiology has also shown the existence of several
obviousmolecular subtypes (or genotypes) of HTLV-1 linked to the
geographical origin of the infected population.32
There are several limitations to our present work. First, we
could not exclude a failure to detect an association due to the small
sample size. The relatively smaller number of participants by
comparison with the Japanese study could be a possible reason for
the failure to replicate earlier positive ﬁndings. However, our
cohort of French Afro-Caribbean HCs originating from Martinique
represents an ethnically homogeneous population from a well-
deﬁned geographical area of 1100 km2 and with a target
R. Deschamps et al. / International Journal of Infectious Diseases 14 (2010) e986–e990e990population of about 400 000. Concerning HLA-A*02, a lower
frequency was observed in our healthy controls compared with
HAM/TSP patients, and it seems unlikely that statistical signiﬁ-
cance for a protective effect would be achieved by increasing the
sample size.
Another explanation for our failure to replicate ﬁndings in this
genetic association study is misclassiﬁcation of outcome.33 In
other words, genotyping could have beenmeasured before disease
onset in HCs. Nevertheless, although average age was lower for our
HCs than symptomatic patients, the mean age of our HCs was
nearly 57 years and the average age at which a diagnosis of HAM/
TSP is usually made is between 40 and 50 years.18,34 Furthermore,
the estimated lifetime cumulative risk of carriers developing
myelopathy is very low, less than 4%. Finally,mean follow-up times
were comparable between the two groups of participants (Table 1).
In conclusion, in our French Afro-Caribbean cohort, we failed to
show any statistically signiﬁcant association of susceptibility or
protection to HAM/TSP and to proviral load with the HLA class I (A
and B) and class II (DRB1 and DQB1) alleles, in particular the HLA-
A*02 allele. The lack of a consistent association in our study and the
conﬂicting results found in prior reports conﬁrm that the
immunogenetic backgrounds responsible for susceptibility to
HAM/TSP differ greatly in diverse ethnic groups. The same
conclusions have previously been drawn for other infectious
diseases.35,36 Moreover, a literature analysis revealed that even in
similar ethnic populations, results are sometimes divergent. The
inﬂuence of HLA genes on HAM/TSP risk and on proviral load level
is complex and our datamay suggest the role of non-HLA candidate
genes in determining the outcome of HTLV-1 infection.
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